GERMANTOWN, Md., Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will ...

Synuclein alpha (SNCA) is a mysterious protein. It’s present in healthy cells but we don’t know what it does there. It is notorious for its involvement in age-related neurodegenerative diseases.

- Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

Th, Dat1, Snca and Bdnf were the genes whose mRNA levels in the ventral tegmental area of the midbrain were measured in male mice that were victorious in 20 daily agonistic interactions and in a group ...